CN103619840B - (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物 - Google Patents

(s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物 Download PDF

Info

Publication number
CN103619840B
CN103619840B CN201280030432.6A CN201280030432A CN103619840B CN 103619840 B CN103619840 B CN 103619840B CN 201280030432 A CN201280030432 A CN 201280030432A CN 103619840 B CN103619840 B CN 103619840B
Authority
CN
China
Prior art keywords
compound
cancer
polymorph
formula
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280030432.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103619840A (zh
Inventor
I·S·高鲁
C·高尔
F·斯托维瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103619840A publication Critical patent/CN103619840A/zh
Application granted granted Critical
Publication of CN103619840B publication Critical patent/CN103619840B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280030432.6A 2011-06-21 2012-06-19 (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物 Expired - Fee Related CN103619840B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499222P 2011-06-21 2011-06-21
US61/499,222 2011-06-21
PCT/EP2012/061756 WO2012175522A1 (en) 2011-06-21 2012-06-19 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide

Publications (2)

Publication Number Publication Date
CN103619840A CN103619840A (zh) 2014-03-05
CN103619840B true CN103619840B (zh) 2016-01-20

Family

ID=46319784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280030432.6A Expired - Fee Related CN103619840B (zh) 2011-06-21 2012-06-19 (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物

Country Status (11)

Country Link
US (1) US9006270B2 (enExample)
EP (1) EP2723733A1 (enExample)
JP (1) JP2014517049A (enExample)
KR (1) KR20140033432A (enExample)
CN (1) CN103619840B (enExample)
BR (1) BR112013032687A2 (enExample)
CA (1) CA2839621A1 (enExample)
IN (1) IN2014DN00145A (enExample)
MX (1) MX2013014887A (enExample)
RU (1) RU2014101626A (enExample)
WO (1) WO2012175522A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
KR20150002623A (ko) * 2012-03-30 2015-01-07 노파르티스 아게 신경모세포종, 유잉 육종 또는 횡문근육종의 치료에 사용하기 위한 화합물
CA2930359C (en) * 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CA2962714C (en) * 2014-10-03 2023-09-19 Novartis Ag Pharmaceutical compositions comprising alpelisib
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
CN112961090A (zh) * 2019-12-13 2021-06-15 武汉九州钰民医药科技有限公司 合成Alpelisib的关键中间体及其制备方法
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
JP7649637B2 (ja) 2020-10-06 2025-03-21 エルジー ディスプレイ カンパニー リミテッド 伝送装置及び表示システム
WO2022234408A1 (en) * 2021-05-03 2022-11-10 Novartis Ag Alpelisib formulation
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035795A (zh) * 2004-10-07 2007-09-12 贝林格尔·英格海姆国际有限公司 噻唑基二氢吲唑
CN101484452A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035795A (zh) * 2004-10-07 2007-09-12 贝林格尔·英格海姆国际有限公司 噻唑基二氢吲唑
CN101484452A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Also Published As

Publication number Publication date
MX2013014887A (es) 2014-02-17
RU2014101626A (ru) 2015-07-27
US9006270B2 (en) 2015-04-14
KR20140033432A (ko) 2014-03-18
IN2014DN00145A (enExample) 2015-05-22
JP2014517049A (ja) 2014-07-17
CA2839621A1 (en) 2012-12-27
EP2723733A1 (en) 2014-04-30
AU2012274141B2 (en) 2015-12-24
AU2012274141A1 (en) 2013-12-12
WO2012175522A1 (en) 2012-12-27
US20140171470A1 (en) 2014-06-19
CN103619840A (zh) 2014-03-05
BR112013032687A2 (pt) 2016-08-30

Similar Documents

Publication Publication Date Title
CN103619840B (zh) (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
US11613536B2 (en) Heterocyclic compounds as immunomodulators
US11718605B2 (en) Heterocyclic compounds as immunomodulators
US11401279B2 (en) Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN109563075B (zh) Tlr7/8拮抗剂及其用途
JP6882299B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
CN107074859B (zh) 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物
TWI775556B (zh) 用於抑制精胺酸酶活性之組合物及方法
KR20240101561A (ko) Kras의 저해제로서의 퀴놀린 화합물
TW202003511A (zh) 作為免疫調節劑之雜環化合物
CN110944990A (zh) Tlr7/8拮抗剂及其用途
CN110678462B (zh) Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法
CN110386944B (zh) 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
CA3170503A1 (en) Stat degraders and uses thereof
CA3202198A1 (en) Cocrystal of a cdk inhibitor
CN102356085A (zh) 具有脯氨酸环结构的咪唑并噻唑衍生物
JP2023549187A (ja) 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
US20070197609A1 (en) Salts of inducible nitric oxide synthase dimerization inhibitors
AU2012274141B8 (en) Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JP2023550609A (ja) 貧血の処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシピロリジン－２－カルボキサミド誘導体
HK1241858A1 (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20170619

CF01 Termination of patent right due to non-payment of annual fee